X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Vetter Once Again Wins Axia Best Managed Companies Award

Content Team by Content Team
7th June 2021
in News
Vetter Once Again Wins Axia Best Managed Companies Award

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

For the second time in a row, Vetter has won the Axia Best Managed Companies Award. The company was again honored for its clear vision, innovative approaches, sustainable management culture and sound financial management. Every year, Deloitte Private, the prominent German business journal WirtschaftsWoche, Credit Suisse and the Bundesverband der Deutschen Industrie (the Federation of German Industries) select which medium-sized companies are best managed and thus receive the renowned award. In keeping with the current pandemic situation, the ceremony was held on a small scale at the headquarters of the family-owned company in Ravensburg.

Once again, Vetter has proven that stability and progress are possible – even during these challenging times. The company presented convincing evidence in the evaluated categories – starting with the competent handling of the current challenges posed by the COVID-19 pandemic, to the successful acquisition of a new production site in Vorarlberg, Austria, as well as its new company strategy, Vetter Next 2029, which is currently in progress.

The Axia Best Managed Companies Program is established in over 30 countries. By winning the award, recipients become part of an exclusive national and global network of successful companies. The three-stage application process is very demanding. The companies’ performance in the key categories strategy, productivity and innovation, culture and commitment, as well as finance and governance are analyzed. As a last step, an independent jury consisting of high-ranking representatives from business, science and the media must also weigh in on the best choice for a winner. The award-winning companies were able to demonstrate an outstanding performance pursuant to the criteria and exemplary best practices.

“From the development of visionary strategies and innovative processes to effective corporate governance structures and a healthy corporate culture – as an award winner, Vetter is characterized by entrepreneurial excellence. Once again, they have set new standards in several key areas of corporate governance,” emphasized Lutz Meyer, partner and head of Deloitte Private.

“This award is dedicated to our 5,500 staff members worldwide,” said Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the owner family. “The special spirit of our family-owned company is particularly evident in these challenging times.” For the company and its staff members, winning the award once again is considered both a trusted confirmation and a strong motivation. Managing Directors Thomas Otto and Peter Soelkner shared, “We are honored to receive the Axia Best Managed Companies Award for the second time in a row. Vetter is focused on acting in a proactive and sustainable manner – now and into the future.”

Previous Post

UPS Healthcare Accelerates Cold Chain Capabilities

Next Post

Serum Institute gets DCGI nod to manufacture Sputnik V COVID-19 vaccine in India

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trials

Serum Institute gets DCGI nod to manufacture Sputnik V COVID-19 vaccine in India

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In